The launch of a new RA biosimilar is being held up in court—and the outcome of the lawsuit will have far-reaching impact on prices. Jeremy Schafer, Precision for Value Senior Vice President and director of the Access Experience Team, explains why in formularywatch.
To read the full article, please click here.